Global Cord Blood & Tissue Banking Industry Report, 2022 – Market Size, Segmentation, Forecasts, Competitors, Opportunities, and Trends
Through Monday, January 24th only, you can claim this report for an unusual 20% off. Act fast, because this offer expires soon.
Market Report, 254 Pages
Today, more than 70% of the global cord blood market is controlled by the world’s 12 largest cord blood banking operators. For both therapeutic and financial reasons, the cord blood industry has been witnessing record levels of merger and acquisition (M&A) activity in recent years, with market leaders gaining market share at the expense of smaller competitors and investors vying for buy-in opportunities. Novel pricing strategies, product cross-sells and upsells, and ingenious online and offline marketing strategies are being implemented by the industry’s market leaders. Meanwhile, new technologies to support ex vivo cord blood expansion are advancing at brisk pace.
Substantial cord blood industry consolidation has happened in recent years and investor appetite for cord blood banks has never been stronger. This is because cord blood banks produce stable subscription revenue from long-term storage contracts. At a fundamental level, cord blood banks are both a real estate investment (cryogenic storage facilities) and a regenerative medicine (RM) play.
In addition to an aggressive M&A environment, a growing number of cord blood banks have been venturing into new types of stem cell storage, reproductive services, and related cell therapy applications. Specifically, cord blood, cord tissue, placental blood and tissue, and amniotic fluid have demonstrated intriguing therapeutic promise, causing storage services for these biomaterials to proliferate.
Cord blood has the potential to be an important source of therapeutic cells for a growing range of regenerative medicine applications. According to ClinicalTrials.gov, there are at least 1,200 clinical trials evaluating the use of cord blood stem and progenitor cells. These studies use unmanipulated whole cord blood (total nucleated cells/TNC), mononuclear cells (MNC), or cord blood-derived mesenchymal stem cells (MSCs). These studies are targeting clinical indications that range from pulmonary diseases to infertility to orthopedic conditions, but the most common area of research is neurologic conditions—such as cerebral palsy, autism, stroke, and hypoxic ischemic encephalopathy.
Within the research realm, cord blood products (fresh and cryopreserved) are being offered by a diverse range of major market leaders, including Lonza, STEMCELL Technologies, AllCells, and dozens of others. Within the therapeutic realm, a growing number of companies are exploring the development and commercialization of perinatal products across a diverse range of applications.
Cord Blood Report Highlights
Overall, the report answers the following questions:
- Number of cord blood units cryopreserved in public and private cord blood banks globally
- Number of hematopoietic stem cell transplants (HSCTs) globally using cord blood cells
- Utilization of cord blood cells in clinical trials for developing regenerative medicines
- The decline of the utilization of cord blood cells in HSC transplantations since 2005
- Emerging technologies to influence financial sustainability of public cord blood banks
- The future scope for companion products from cord blood
- The changing landscape of cord blood cell banking market
- Extension of services by cord blood banks
- Types of cord blood banks
- Economic model of public cord blood banks
- Cost analysis for public cord blood banks
- Economic model of private cord blood banks
- Cost analysis for private cord blood banks
- Profit margins for private cord blood banks
- Pricing for processing and storage in private banks
- Rate per cord blood unit in the U.S. and Europe
- Indications for the use of cord blood-derived HSCs for transplantations
- Diseases targeted by cord blood-derived MSCs in regenerative medicine
- Cord blood processing technologies
- Number of clinical trials, number of published scientific papers and NIH funding for cord blood research
- Transplantation data from different cord blood registries
Key questions answered within the report are:
- What are the strategies being considered to improve the financial stability of public cord blood banks?
- What are the companion products proposed to be developed from cord blood?
- How much is spent to process and store a unit of cord blood?
- How much does a unit of cryopreserved cord blood unit fetch on release?
- Why do most public cord blood banks incur a loss?
- What is the net profit margin for a private cord blood bank?
- What are the prices for processing and storage of cord blood in private cord blood banks?
- What are the rates per cord blood units in the U.S. and Europe?
- What are the revenues from cord blood sales for major cord blood banks?
- Which are the different accreditation systems for cord blood banks?
- What are the comparative merits of the various cord blood processing technologies?
- What is to be done to increase the rate of utilization of cord blood cells in transplantations?
- Which TNC counts are preferred for transplantation?
- What is the number of registered clinical trials using cord blood and cord tissue?
- How many clinical trials are studying the ex vivo expansion of cord blood?
- How many matching and mismatching transplantations using cord blood units are performed on an annual basis?
- What is the share of cord blood transplants compared to bone marrow and peripheral blood transplants from 2000 to 2021?
- What is the likelihood of finding a matching allogeneic cord blood unit by ethnicity?
- Which are the top ten countries for donating cord blood?
- What are the diseases targeted by cord blood and tissue derived MSCs within clinical trials?
At 254 pages in length, this global strategic report presents a comprehensive snapshot of the cord blood and tissue banking market. It includes a detailed market size determination, with breakdown by geography, indication, and type of bank, as well as future projections for each segment through 2027. It reveals the number of cord blood units stored in inventory by the largest cord blood banks worldwide, as well as the total storage count for both public and private units in storage worldwide. It also presents the number of cord blood units (CBUs) released by registries across the world for hematopoietic stem cell transplantation (HSCT).
It reveals the identities of companies offering cord blood storage, cord blood processing technologies, cord blood expansion technologies, and cord blood therapeutics on a global basis. It provides coverage of recent M&A transactions, including the consolidation plans executed by the twelve largest cord blood operators worldwide. Although cord blood is now used to treat 80 different diseases, this number will expand as regenerative medicine applications begin to receive approvals in major healthcare markets worldwide.
Given the accelerating complexity and competitive nature of this global market, you don’t have the time to do the research. Claim this market report to become immediately informed, without sacrificing hours of unnecessary research. BioInformant has tracked this market since 2006, providing it with an unprecedented 15-year historical data set on which to make future market predictions.
VIEW TABLE OF CONTENTS: Global Cord Blood & Tissue Banking Industry Report, 2022
With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 15 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capital Hill.
The content within this report was compiled using a diverse range of sources, as described in this Research Methodology. To select a License Type, click here.
Remember, all BioInformant products come with a Greater Than 100% Money Back Guarantee. If the strategies and tools aren’t helpful to you – we’ll cheerfully refund your money, and you can keep the product.
Have questions? Email us at Info@BioInformant.com to get a rapid reply. Checkout below to get immediate access to this report, with printing rights allowed.